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The development of postoperative complications after 
major non- cardiac surgery — particularly acute kidney 
injury (AKI) — has consistently been associated with 
substantial long- term morbidity and mortality1–4. AKI 
can be considered a sentinel postoperative complica-
tion that is strongly associated with increased risk of 
death, co- occurrence of other postoperative complica-
tions, increased length of hospital stay and the devel-
opment of progressive chronic kidney disease (CKD), 
which results in a considerable health- care and societal 
burden5–7.
Considerable research and previous consensus 
meetings have focused on AKI after cardiac surgery8. 
However, the role of AKI after other forms of major 
surgery, particularly gastrointestinal surgery, has 
received less attention, even though such procedures 
are associated with higher 30- day mortality than many 
forms of cardiac surgery9. Despite the importance of AKI 
as a complication after all forms of major surgery, lack 
of consensus exists with regard to the definition, pre-
vention and treatment of postoperative AKI (PO- AKI) 
and the pathophysiology of PO- AKI in the non- cardiac 
setting has not been well described. Furthermore, the 
understanding of and approach to this condition can 
differ between specialists in nephrology, anaesthesia 
and/or perioperative medicine.
In 2019, a joint meeting of the Acute Disease 
Quality Initiative (ADQI-24) and the PeriOperative 
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Abstract | Postoperative acute kidney injury (PO- AKI) is a common complication of major surgery 
that is strongly associated with short- term surgical complications and long- term adverse outcomes, 
including increased risk of chronic kidney disease, cardiovascular events and death. Risk factors  
for PO- AKI include older age and comorbid diseases such as chronic kidney disease and diabetes 
mellitus. PO- AKI is best defined as AKI occurring within 7 days of an operative intervention using  
the Kidney Disease Improving Global Outcomes (KDIGO) definition of AKI; however, additional 
prognostic information may be gained from detailed clinical assessment and other diagnostic 
investigations in the form of a focused kidney health assessment (KHA). Prevention of PO- AKI is 
largely based on identification of high baseline risk, monitoring and reduction of nephrotoxic insults, 
whereas treatment involves the application of a bundle of interventions to avoid secondary kidney 
injury and mitigate the severity of AKI. As PO- AKI is strongly associated with long- term adverse 
outcomes, some form of follow- up KHA is essential; however, the form and location of this will be 
dictated by the nature and severity of the AKI. In this Consensus Statement, we provide graded 
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Quality Initiative (POQI-7) was convened to address 
PO- AKI after major non- cardiac surgery. Here, we pres-
ent our recommendations for clinical practice as well as 
for further research in this important area.
Methods
The Conference Chairs of the 24th ADQI/7th POQI 
consensus committee (J.R.P., J.A.K., A.D.S. and L.G.F.) 
convened a diverse panel of clinicians and researchers 
representing relevant disciplines (internal medicine, 
nephrology, critical care, anaesthesia, perioperative 
medicine, pharmacy and surgery) from Europe, North 
America and Australia, to discuss the issues relating to 
PO- AKI. The consensus meeting was held at Emmanuel 
College, Cambridge, UK, on 4–7 September 2019, and 
followed the established ADQI process and POQI 
protocols, including use of a modified Delphi method to 
achieve consensus8,10. The broad objective of ADQI 24 
was to produce expert- based statements and a summary 
of current knowledge pertaining to the definition and 
management of PO- AKI in the setting of non- cardiac 
surgery for use by clinicians and researchers, based on 
review of evidence by and professional judgment of the 
faculty as well as to identify evidence gaps to establish 
research priorities.
Conference participants were divided into five work 
groups: group 1 was tasked with the epidemiology and 
pathophysiology of PO- AKI. Group 2 was tasked with 
developing a definition for PO- AKI. Group 3 devel-
oped recommendations for the prevention of PO- AKI. 
Group 4 focused on treatment options for patients with 
PO- AKI, and group 5 explored outcomes after PO- AKI 
(Supplementary Information). Members of the work 
groups performed comprehensive literature searches 
and developed a consensus of opinion, backed by evi-
dence where possible, to distil the available literature 
and articulate a research agenda to address important 
unanswered questions. Members assessed the level of 
evidence and strength of recommendation for all con-
sensus statements using the GRADE evidence to deci-
sion frameworks11. A number of ungraded research 
recommendations were also identified in areas where 
high- quality evidence is lacking. Strength of recommen-
dations and aggregated conclusions were established by 
consensus of all of the participants, who formally voted 
and approved the consensus recommendations.
Pathophysiology and epidemiology
Like all forms of AKI, PO- AKI represents a clinical syn-
drome rather than a single disease and limited histo-
logical data from kidney biopsy samples are available 
to identify specific pathology12,13 (Box 1). Animal mod-
els that are used to study AKI pathophysiology tend to 
employ a single insult to the kidneys rather than explore 
the multifactorial insults that are common in clinical 
practice14–18. However, commonly implicated mech-
anisms for PO- AKI include ischaemia–reperfusion 
injury, endogenous or exogenous nephrotoxins, phys-
ical causes such as obstruction, inflammatory factors, 
vasoconstriction, and oxidative stress19 (Fig. 1). Thus, 
a variety of exposures that are encountered in the surgi-
cal setting are involved in the development of PO- AKI20. 
Many of these exposures might also have a role in other 
forms of AKI, but their relative importance, severity and 
timing in PO- AKI may differ from that of other AKI 
settings. Within this framework, the contribution of 
individual mechanisms is often difficult to determine; 
for instance, nephrotoxic drugs have been implicated in 
20–30% of all AKI episodes and are commonly encoun-
tered in the surgical setting21. Moreover, agents such 
as radiocontrast and antibiotics are commonly used in 
patients who are already at risk of AKI and discerning 
their relative contribution to the overall AKI course is 
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often difficult. Future research including studies aimed 
at understanding the interplay between concomitant 
perioperative complications might help to identify the 
underlying pathophysiological mechanisms of PO- AKI.
Epidemiology of postoperative AKI. A variety of criteria 
for changes in serum creatinine levels and urine output 
have been used to define AKI; however, the periopera-
tive medicine community has largely adopted the 2012 
Kidney Disease: Improving Global Outcomes (KDIGO) 
consensus criteria to define PO- AKI in clinical trials 
and epidemiological studies22. Adoption of this con-
sensus definition has resulted in a greater appreciation 
of the incidence, varied presentation and outcomes of 
PO- AKI (Box 1). Although changes in serum creatinine 
are fairly common in the postoperative period, the inci-
dence of PO- AKI varies according to the characteristics 
and urgency of surgery as well as the exact AKI defini-
tion employed, with a higher incidence in emergency 
surgery2,4,23–31 (Supplementary Table 1). The incidence 
of AKI in day or ambulatory surgery is unknown — 
but presumed to be low — owing to a lack of published 
data on the detection of AKI among patients who are 
discharged to the community immediately following 
surgery.
More is known about PO- AKI defined by change 
in serum creatinine than that defined by perioperative 
decrements in urine output. The prognostic implications 
of intraoperative transient oliguria are controversial, 
with some studies reporting a higher risk of subsequent 
adverse outcomes and others suggesting no increase 
in risk32–35. One study suggested that discrimination 
for subsequent adverse outcomes could be enhanced 
by testing for novel biomarkers. In this study, which 
included some patients with PO- AKI, the sum of the 
concentration of tissue inhibitor of metalloproteinases 2 
(TIMP2) multiplied by that of insulin- like growth 
factor binding protein 7 (IGFBP7) added prognos-
tic information to AKI defined by urine output alone 
([TIMP2]×[IGFBP7] > 2 was associated with progression 
from stage 1 AKI)36.
Many, but not all, of the available studies suggest that 
PO- AKI defined by oliguria alone is more common 
than PO- AKI defined by changes in serum creatinine 
levels26,37–39. In a study of PO- AKI after non- cardiac sur-
gery, the incidence of AKI increased from 8% to 64% if 
urine output was included in the definition37. Some post-
operative oliguria is assumed to be an appropriate phys-
iological response to decreased intravascular volume, 
vasodilatation or non- osmotic release of arginine vaso-
pressin in response to tissue injury40; however, sustained 
decrements in urine output, even without accompanying 
changes in serum creatinine, have been associated with 
longer- term morbidity and mortality38,41.
Epidemiology of postoperative AKD
The concept of acute kidney disease (AKD) is intended 
to bridge the gap between AKI, which refers to an acute 
alteration in kidney function over a 7- day period, and 
CKD, which refers to a sustained alteration in kidney 
function over a 3- month period. AKD therefore refers 
to AKI that persists for more than 7 days after the initial 
insult, or a progressive decline in kidney function that 
does not meet AKI criteria on a week- by- week basis. Few 
epidemiological data are available on the incidence and 
prognosis of postoperative AKD, despite its likely impor-
tance as a bridge to development of sustained kidney 
dysfunction and CKD42. A study that evaluated substan-
tial decline in kidney function, defined as a 30% decrease 
in estimated glomerular filtration rate at 60 days after 
surgery, suggested that the incidence of this outcome was 
only 2% among patients without PO- AKI (defined by 
change in serum creatinine only), but 10%, 17% and 29% 
among patients who experienced PO- AKI stages 1, 2, 
and 3, respectively43. The incidence of AKD in the gen-
eral population is likely lower than in the post- surgery 
population; in a study of Canadian electronic health 
records, 5.2% of patients in a given period had AKD 
with or without AKI44.
Risk factors for postoperative AKI. Several patient- 
related, surgery- related, and anaesthetic- related risk 
factors for developing early PO- AKI during the first 
48 h after surgery have been described4,40. The three 
validated risk scores for PO- AKI include male sex, age 
>50 years, diabetes mellitus, hypertension, ascites, heart 
failure, emergent surgery, intraperitoneal surgery, poly- 
pharmacy, use of an angiotensin- converting enzyme 
(ACE) inhibitor or angiotensin receptor blocker (ARB), 
and increasing American Society of Anesthesiologists 
physical status classification score34,45,46. Albuminuria 
and hypoalbuminaemia have also been described as risk 
factors for PO- AKI47–50. Risk factors for PO- AKI occur-
ring in patients in the ICU more than 48 h after surgery 
reflect risk factors for AKI in critical illness including 
the need for new nephrotoxic medication, sepsis and 
shock51,52. Whether targeting modifiable risk factors for 
Box 1 | pathophysiology and epidemiology of po- AKI
Consensus Statement 1a
Postoperative acute kidney injury (PO- aKi) is a clinical syndrome rather than a single 
disease. the majority of cases of PO- aKi are multifactorial in cause (ungraded).
Consensus Statement 1b
the incidence of PO- aKi (defined by changes in serum creatinine) varies with the 
characteristics and urgency of surgery. the incidence of aKi after day or ambulatory 
surgery is uncertain (ungraded).
Consensus Statement 1c
aKi defined by transient oliguria is more common in the intraoperative and 
postoperative period than aKi defined by serum creatinine. severe oliguria and anuria, 
even in the absence of changes in serum creatinine, are associated with increased 
long- term morbidity and mortality (ungraded).
Consensus Statement 1d
the majority of observational studies focus on aKi in the immediate postoperative 
period. Little evidence is available regarding the epidemiology of acute kidney disease 
in the perioperative setting (ungraded).
Consensus Statement 1e
risk factors for PO- aKi include age >50 years, male sex, glomerular filtration rate 
<60 ml/min/1.73 m2, diabetes mellitus, heart failure, ascites, hypertension, emergency 
surgery, intraperitoneal surgery, number of medications, use of angiotensin- converting 
enzyme (aCe) inhibitors or angiotensin receptor blockers (arBs), high american 
society of anesthesiology Physical status classification score and albuminuria. Patients 
with chronic kidney disease (CKD) and/or diabetes are at a particularly high risk of aKi 
(ungraded).
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early PO- AKI, for example, using perioperative haemo-
dynamic interventions, will impact the incidence of AKI 
later in the postoperative period, >48 h after surgery, 
remains uncertain.
Use of a validated clinical risk score is a potentially 
useful approach to risk stratify patients for targeted 
interventions or to facilitate the conduct of randomized 
controlled trials (RCTs)53. However, existing validated 
risk scores for PO- AKI were developed using a vari-
ety of older (pre- KDIGO) definitions of AKI or were 
applied to select surgical settings34,45,46. More generaliz-
able prognostic clinical tools are needed to accurately 
risk- stratify patients preoperatively, particularly to dis-
tinguish those patients at the highest levels of risk (e.g. 
>20–30%). In the absence of such tools, patients with 
CKD and those with diabetes can reasonably be con-
sidered to be at increased risk of PO- AKI. The KDIGO 
guideline for the diagnosis, evaluation and management 
of AKI suggests that age >60 years, emergency surgery, 
elevated American Society of Anesthesiologists physi-
cal status classification score and preoperative comorbid 
illnesses, including diabetes and any chronic disease of 
the heart, lung or liver, are risk factors for PO- AKI42.
Research recommendations. Understanding the patho-
physiology and epidemiology of PO- AKI is central to 
the identification and development of novel preventa-
tive therapies and treatments. This understanding may 
be improved by conducting prospective studies that 
include collection of biological samples for histologi-
cal and biomarker examination as well as retrospective 
analyses that examine shared pathogenesis across a 
spectrum of perioperative complications. The incidence 
of PO- AKI in the day and ambulatory surgery settings 
is uncertain and should be investigated in epidemiolog-
ical studies. Development of better risk prediction tools 
for PO- AKI could help to risk- stratify patients and set 
thresholds of predicted risk that merit adjustments in 
perioperative care.
Definition of postoperative AKI
Although the KDIGO definition of AKI is now widely 
employed in the perioperative literature, the exact imple-
mentation of this definition varies considerably in terms 
of timeframe of diagnosis. We recommend defining 
PO- AKI as occurring when existing KDIGO criteria for 
AKI are met within 7 days of an operative intervention 
(Box 2). AKI occurring de novo ≥7 days after surgery 
may arise in a variety of contexts that are not necessarily 
related to the surgery itself; we recommend that such AKI 
should be evaluated and managed as hospital- acquired 
AKI. Our recommendation for using a 7- day window 
is somewhat arbitrary but maintains important con-
sistency with the KDIGO definitions for AKI in other 
clinical contexts54 and is supported by evidence from 
numerous clinical studies51,55–57. Furthermore, within the 
7- day window, different timing of AKI may be indicative 
of the nature of the kidney insult, that is, intra- operative 
events versus post- operative insults.
Notably, AKI could potentially be present before sur-
gery (for example, in patients with sepsis requiring surgi-
cal intervention, acute trauma or preoperative contrast 
exposure), highlighting the importance of a risk- based 
kidney health assessment (KHA)51. Use of a KHA was pre-
viously recommended by ADQI in the context of quality 
improvement processes for monitoring patients at a high 
risk of AKI before surgery58. A KHA comprises a struc-
tured evaluation that includes previous history of AKI, 
current medications, cardiovascular health, haemody-
namic status and markers of kidney function (i.e. serum 
creatinine) and kidney damage (i.e. urine dipstick). Use 
of a KHA in the perioperative period involves integrated 
assessment of patient- specific and procedure- specific risk 
factors, clinical context and resource setting.
Importantly, the KHA approach can be used to 
perform context- dependent evaluation both before 
and after surgery, when AKI is diagnosed and during 
follow- up (Fig. 2). A perioperative KHA may range from 
a simple history and physical examination conducted as 
part of a routine low- risk preoperative evaluation, to an 
evaluation that includes more specific measures such 
as urinalysis to identify proteinuria, biomarkers of kid-
ney damage and kidney imaging in higher- risk patients 
(Box 2). Measurements other than serum creatinine 
and urine output are not currently part of the KDIGO 
AKI definition, but likely provide important context for 
enhanced interpretation of these criteria. Although we 
strongly support routine use of KHAs before and after 
surgery, the potential clinical benefit of this approach has 
not been formally evaluated and so remains uncertain. 
However, an accepted advantage of routine perioperative 
KHAs is improved recognition of preoperative kidney 
dysfunction, which establishes a baseline for subsequent 
diagnosis of PO- AKI.
Preoperative factors 
• Pre-existing kidney 
dysfunction 
• Diabetes
• Cardiac dysfunction 
• Age > 50 years
• Sepsis
• Volume depletion 
• Hepatic failure
• Crush injury
• Exposure to nephrotoxins
Intraoperative factors
• Hypovolaemia (caused by 






• Decreased cardiac output 
(caused by anaesthetic) 
• Vasodilatation (caused by 
anaesthetic) 
• Exposure to nephrotoxins
• Embolism
Postoperative factors
• Hypovolaemia (caused by 






• Decreased cardiac output 
(caused by anaesthetic) 
• Vasodilatation (caused by 
anaesthetic) 
• Exposure to nephrotoxins
• Urinary obstruction











Fig. 1 | pathophysiology of po-AKI. Similar to most other forms of acute kidney injury 
(AKI), postoperative AKI (PO- AKI) commonly has a multifactorial aetiology, which is 
mediated by common injury pathways that affect the kidney microcirculation, oxygen 
demand and inflammation. In most cases, a combination of preoperative risk factors, 
intraoperative events and postoperative events leads to the development of AKI.  
Baseline risk factors and the persistence and severity of injurious factors in the 
postoperative setting also determine the outcomes of AKI, acute kidney disease and 
eventually chronic kidney disease. Adapted from Acute Disease Quality Initiative 24, 
www.ADQI.org, CC BY 2.0 (https://creativecommons.org/licenses/by/2.0/).
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Conventional diagnostic criteria for AKI might be 
influenced by multiple factors specific to the periopera-
tive period, rendering their predictive utility for PO- AKI 
less certain. Serum creatinine concentration is subject 
to abrupt changes in total body water59, which may spu-
riously increase or decrease measured values, as well 
as perioperative changes in creatinine production that 
alter serum creatinine levels independently of changes 
in GFR60. Urine output is also likely to be influenced 
by multiple physiological factors specific to the periop-
erative period, including intravascular volume status, 
relative or absolute hypotension and neurohormonal 
response to surgery. Data suggest that although intra-
operative oliguria is associated with PO- AKI, the posi-
tive predictive value is low32. We therefore recommend 
that urine output is interpreted in the context of severity 
of oliguria, clinical setting and other corroborating evi-
dence of PO- AKI. Thus, isolated perioperative oliguria 
meeting AKI stage 1 criteria in the context of transient 
hypotension should not be viewed as being the same as 
more severe or prolonged oligo- anuria unresponsive to 
haemodynamic interventions. The presence of new evi-
dence of kidney tubular damage (e.g. on urine micros-
copy or from novel biomarkers) or evidence of evolving 
sepsis in the context of early oliguria would be suggestive 
of AKI; these factors can be identified and integrated 
within a timely postoperative KHA.
Definition of postoperative AKD. Consistent with the 
definition of AKD as a condition in which AKI stage 1 or 
greater is present ≥7 days after an AKI initiating event, 
postoperative acute kidney disease (PO- AKD) occurs in 
patients with PO- AKI who continue to meet KDIGO 
criteria for AKI >7 days after surgery. Patients whose 
rise in serum creatinine level begins before postoperative 
day 7 but whose serum creatinine level does not increase 
≥50% above baseline until 7–90 days after surgery would 
also meet PO- AKD criteria based on a slow progressive 
deterioration in kidney function in the postoperative 
period (Box 2). However, the greater the time interval 
between surgery and identification of kidney injury the 
less likely that the injury could be attributed to the peri-
operative process. Patients who meet criteria for AKI 
for the first time after postoperative day 7 without any 
previous increase in serum creatinine should therefore 
be referred to as having AKI54 or AKD61 without the 
postoperative prefix. With this proposed nomenclature 
(Fig. 3), it sought to combine a level of consistency with 
existing recommendations for use of AKI and AKD 
terminology54,61. However, revision may be warranted 
as our understanding of the pathophysiology and 
prognostic implications of temporal variations in the 
postoperative disease course evolves.
Research recommendations. Limited information exists 
regarding the prognostic implications of the nature and 
timing of the AKI diagnosis within 7 days after surgery, 
and these important aspects of the PO- AKI diagnostic 
criteria warrant better characterization. Furthermore, 
to what extent indices of kidney injury other than 
serum creatinine and urine output, such as urinary or 
plasma biomarkers, are important for prognostication in 
PO- AKI is unknown and should be the subject of fur-
ther study. Whether or not important differences exist 
in the epidemiology and prognostic significance of 
PO- AKD that arises as persistent PO- AKI compared 
with PO- AKD that develops after a gradual rise in 
creatinine after day 7 is also unknown.
The impact of routine, structured KHA on the detec-
tion of PO- AKI remains to be determined. An expanded 
perioperative urinalysis conducted as part of a detailed 
KHA might identify previously unknown pathology and 
could potentially lead to additional, potentially expen-
sive and/or invasive investigations that could delay 
surgery. The presumed benefits and cost- effectiveness 
of a KHA therefore require confirmation. Finally, the 
optimal interpretation of intraoperative and postoper-
ative oliguria remains unclear and should be the subject 
of further study.
Prevention of postoperative AKI
Preoperative strategies. Surgery is sometimes performed 
in patients with established AKI; however, common 
perioperative interventions focus on prevention of 
PO- AKI (Box 3). As nephrotoxic drugs are an important 
preventable contributor to the risk of PO- AKI, exposure 
to these drugs should be limited whenever possible and 
the benefits of the intervention weighed against the risk of 
developing or worsening AKI62. Although the avoidance 
of potential nephrotoxins is considered to be a corner-
stone of AKI prevention, there is a relative paucity of data 
supporting this approach. However, routine use of genta-
micin for surgical prophylaxis was associated with an 
increased risk of AKI following orthopaedic surgery63 and, 
in the paediatric setting, systematic screening for nephro-
toxin use, with a focus on close monitoring in patients 
exposed to multiple nephrotoxins and nephrotoxin 
cessation, has been shown to reduce rates of AKI64,65.
At present, common practice is to discontinue use 
of ACE inhibitors and ARBs before surgery to avoid 
perioperative hypotension. This approach is assumed 
to reduce the risk of perioperative AKI based on physi-
ological rationale. In line with this established practice, 
we recommend discontinuing ACE inhibitors and ARBs 
for a minimum of 24 h before surgery to minimize the 
risks of perioperative hypotension and/or postopera-
tive AKI (Box 3). This recommendation is weak owing 
to limited data in support of this practice and is likely 
Box 2 | Definition of po- AKI
Consensus Statement 1a
we recommend defining postoperative acute kidney injury (PO- aKi) as occurring when 
existing Kidney Disease improving Global Outcomes (KDiGO) criteria for aKi are met 
within 7 days of an operative intervention (ungraded).
Consensus Statement 1b
we recommend performing a risk- based Kidney Health assessment (KHa) preoperatively 
and postoperatively, with the specific methods and frequency of assessment determined 
by clinical judgement based on individual patient- specific and procedural- specific risk 
factors and the available resources (grade D evidence; strong recommendation).
Consensus Statement 1c
we recommend using the term postoperative acute kidney disease (PO- aKD) when 
KDiGO criteria for aKi are present after postoperative day 7 and objective evidence  
of injury initiation was present within the first 7 postoperative days (ungraded).
Nature reviews | Nephrology
C o n S e n S u S  S tat e m e n t
0123456789();: 
to be revised as more evidence becomes available. For 
instance, an analysis of 949 patients undergoing major 
gastrointestinal or hepatobiliary surgery failed to show 
a difference in the rates of AKI between those who did 
and those who did not have ACE inhibitors and ARBs 
withheld before surgery66.
NSAIDs are generally avoided in surgical patients at 
a high risk of AKI, but might be beneficial as opiate- 
sparing agents in patients who are at a low risk of AKI. 
Although NSAIDs are widely used in patients with nor-
mal kidney function, their impact on risk of AKI in the 












• Nature of proposed procedure
• Drug history
• Baseline kidney function
• Previous episodes of AKI
Optional assessments in those at 
higher baseline risk 
• Urinalysis
• Kidney imaging
• Biomarkers of AKI risk
Preoperative KHA
Integrated assessment of patient-
specific AKI risk before surgery
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Fig. 2 | The role of the KhA in postoperative AKI. Kidney health assessments (KHAs) can be used in the risk assessment, 
detection, management and follow- up of postoperative acute kidney injury (AKI). A series of context- specific KHAs 
involving integration of medical history and clinical context, potentially in combination with further investigations, such 
as analysis of specific kidney biomarkers or imaging, in higher- risk settings, can provide kidney prognostic information to 
guide further monitoring and treatment. AKD, acute kidney disease; CKD, chronic kidney disease. Adapted from Acute 
Disease Quality Initiative 24, www.ADQI.org, CC BY 2.0 (https://creativecommons.org/licenses/by/2.0/).
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To date, no preoperative pharmacological interven-
tion has been shown to reduce the risk of PO- AKI in 
RCTs. However, attention should be paid to ensuring 
euvolaemia prior to surgery and addressing or avoid-
ing preoperative fluid losses caused by excessive fasting, 
bowel preparation and/or acute illness67.
Intraoperative strategies. Intravenous fluid and hae-
modynamic management in the intraoperative and 
early postoperative period has a major impact on the 
development of PO- AKI (Box 4). The RELIEF RCT in 
3,000 patients undergoing major elective non- cardiac 
surgery compared a zero fluid balance target with a 
“moderately liberal” approach to fluid administra-
tion and demonstrated an increased risk of AKI in the 
restrictive, zero fluid balance group68. Algorithms that 
use cardiac output monitoring to optimize cardiac 
stroke volume and/or increase global oxygen delivery, 
known as goal- directed therapy, have been the subject 
of multiple RCTs. A Cochrane review and meta- analysis 
suggested that goal- directed therapy can reduce the risk 
of PO- AKI69,70. Large observational studies have shown 
strong associations between intraoperative hypotension 
and PO- AKI with the risk of organ injury a function 
of the severity and duration of the hypotension71–73. 
Both absolute mean arterial blood pressure (MAP 
(e.g. 60–70 mmHg)) and relative MAP (e.g. <30% reduc-
tion from baseline) thresholds are associated with PO- 
AKI. The results of an interventional trial of use of a 
MAP target of >65 mmHg as part of a goal- directed 
strategy have added weight to these observational 
data, demonstrating fewer postoperative complications 
(including AKI) and shorter length of hospital stay with 
this approach74. Similar to other settings such as sep-
sis, a higher MAP target may be beneficial in reducing 
the incidence of AKI in patients with poorly controlled 
pre- existing hypertension75.
Fluid composition may also affect the risk of PO- AKI; 
0.9% saline is associated with increased risk of PO- AKI 
compared with balanced crystalloids76–78 (Box  4). 
High- quality evidence has shown that use of starch- 
based colloids increases the risk of AKI and other 
adverse outcomes in patients with sepsis and other crit-
ically ill patients79,80. Although caution is advised when 
using starch- based colloids, the limited data in the elec-
tive perioperative setting, where lower fluid volumes 
may be given than in treatment of septic shock, suggest 
little difference in kidney outcomes when starch- based 
colloids are used in preference to crystalloids or 
non- starch colloids81,82. Ongoing research is investigat-
ing use of starch- based colloids versus crystalloids in the 
perioperative setting. One such trial published in 2020 
reported no significant difference in a composite out-
come of death or postoperative complications within 
14 days of major abdominal surgery between patients 
who received low- molecular- weight hydroxyethyl starch 
compared with those who received 0.9% saline83.
Postoperative strategies. The early postoperative period 
has not been extensively studied in relation to kidney 
outcomes. However, therapeutic strategies used in 
the hours after surgery could likely modify the risk of 
AKI (Box 5). Clinically important postoperative hypo-
tension (defined as systolic blood pressure <90 mmHg 
and requiring medical intervention) affects over 30% 
of patients, often goes uncorrected for longer than intra-
operative hypotension and is associated with an increased 
risk of all- cause mortality and myocardial injury84. 
















































Fig. 3 | Conceptual model of po-AKI and po-AKD. Postoperative acute kidney injury 
(PO- AKI) occurs when the Kidney Disease Improving Global Outcomes (KDIGO) criteria 
for AKI are met within 7 days of an operative intervention. Postoperative acute kidney 
disease (PO- AKD) occurs when patients with PO- AKI continue to meet KDIGO AKI 
criteria ≥7 days after surgery or when patients whose serum creatinine levels began  
to rise following surgery meet KDIGO AKI criteria ≥7 days after surgery. A number of 
potential trajectories of serum creatinine are depicted with suggested application  
of the proposed nomenclature. PO- AKI might commence and resolve before postoperative 
day 7 or persist after postoperative day 7 and therefore be classed as PO- AKD. If PO- AKD 
continues after postoperative day 90 it will be classed as chronic kidney disease (CKD) 
(trajectory 1). PO- AKD also occurs when evidence of new kidney injury was present before 
postoperative day 7 but did not meet the criteria for PO- AKI until after postoperative  
day 7. This form of PO- AKD might also either recover before postoperative day 90 or 
continue after postoperative day 90 and be classed as CKD (trajectory 2). Stand- alone 
AKI or AKD (that is, AKI or AKD that is seemingly not related to the operative intervention) 
can also occur during the perioperative period. As these new events occur distant to  
the surgical insult they should not be referred to as PO- AKI or PO- AKD and should be 
considered in the context of their direct precipitants (trajectory 3). Subclinical kidney 
injury can occur before or after postoperative day 7 (trajectory 4). This subclinical injury 
does not meet current criteria for AKI or AKD, but may be identified by risk- based serial 
kidney health assessments (KHAs). Source: Adapted from Acute Disease Quality Initiative 
24, www.ADQI.org, CC BY 2.0 (https://creativecommons.org/licenses/by/2.0/).
Box 3 | prevention of po- AKI: preoperative strategies
Consensus Statement 3a
we recommend that when considering use of medications or interventions that are 
associated with an increased risk of acute kidney injury (aKi), the relative benefits  
and/or necessity of the medications or interventions should be balanced with the risk  
of postoperative aKi (PO- aKi). this recommendation applies to outpatient medications, 
new medications and exposures including contrast media (grade C evidence; strong 
recommendation).
Consensus Statement 3b
we recommend discontinuing angiotensin- converting enzyme (aCe) inhibitors and 
angiotensin receptor blockers (arBs) for a minimum of 24 h before surgery, dependent 
on the specific medication, to minimize the risks of perioperative hypotension and/or 
PO- aKi (grade D evidence, weak recommendation).
Consensus Statement 3c
we recommend assessing the relative risks and benefits of use of NsaiDs (including 
COX2 inhibitors) in individual patients. in general, in patients at a high risk of PO- aKi, 
the risk of aKi associated with use of NsaiDs might outweigh the benefits with regard 
to opioid minimization, whereas in low- risk patients, the benefits of use of NsaiDs 
might outweigh the risks. the risk–benefit profile in patients at a moderate risk of aKi  
is particularly uncertain (grade D evidence; strong recommendation).
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haemodynamic status in the early postoperative phase 
is important to avoid organ injuries including AKI28. 
A trial that used stroke volume optimization and vaso-
pressors to target a MAP within 10% of the preoperative 
baseline value during and for 4 h after surgery showed 
that this strategy was associated with a reduction in post-
operative organ injury, but was not powered to assess 
kidney- specific outcomes85. Further research is war-
ranted to evaluate postoperative monitoring strategies 
and ideal clinical settings to reduce the risk of PO- AKI 
in moderate- to high- risk patients.
As postoperative hyperglycaemia is strongly associ-
ated with AKI, avoidance of perioperative hyperglycaemia 
(>180 mg/dl) is recommended86. Failure to restart 
chronic ACE inhibitor or ARB therapy that was sus-
pended preoperatively is associated with increased 
30- day mortality87,88. However, the optimal time point 
to restart these medications has not been clearly estab-
lished. Given their effects on the kidney, a reasonable 
approach would be to conduct a focused KHA before 
restarting ACE inhibitors or ARBs.
Enhanced recovery after surgery pathways are typ-
ically multimodal, multidisciplinary interventions that 
have been promoted to facilitate recovery from surgery. 
Use of NSAIDs to minimize opiate analgesia require-
ments is a common component of such pathways, along 
with avoidance of markedly positive fluid balance. 
Accordingly, in some settings such as colorectal surgery, 
implementation of an enhanced recovery after surgery 
pathway could be associated with a higher, rather than 
lower, incidence of AKI89.
Treatment of postoperative AKI
As a general principal, treatment of AKI should be 
initi ated as early as possible, including in patients with 
suspected AKI or who are at a substantially increased 
risk of AKI. Management of PO- AKI involves specific 
approaches, for example, avoidance of nephrotoxins, 
as well as general management principles that are com-
mon to all postoperative complications, such as haemo-
dynamic optimization. Similarly, treatment of PO- AKI 
shares many features with the treatment of AKI in other 
settings (TaBle 1). Treatment goals include reducing kid-
ney injury and complications related to decreased kidney 
function.
A full KHA should be performed, including drug 
history, which should focus on potential nephrotoxins, 
including antibiotics and radiocontrast agents. In addition 
to classical evaluation techniques, a number of biomark-
ers of cellular damage and functional change are availa-
ble for the early diagnosis, risk assessment and prognosis 
of AKI90–95. Nephrology or urology consultation should 
be sought if intrinsic causes of AKI or obstruction are 
suspected based on the KHA results. The frequency and 
duration of monitoring should be individualized based 
on patient risk, exposure and clinical course (Box 6).
The KDIGO bundle. The treatment and prevention bun-
dle outlined in the 2012 KDIGO clinical practice guide-
line for AKI consists of supportive measures, including 
volume management, maintenance of adequate blood 
pressure and judicious avoidance of nephrotoxins. Two 
RCTs demonstrated that implementation of this bundle 
in high- risk patients identified by biomarkers after sur-
gery significantly reduced the occurrence of PO- AKI, 
but were not powered to demonstrate differences in 
longer- term patient outcomes96,97. However, observa-
tional studies have shown that the severity of AKI cor-
relates with short- term98–101 and longer- term102 adverse 
events, suggesting that interventions that reduce the 
severity of AKI could improve these outcomes.
Kidney replacement therapy. Kidney replacement ther-
apy (KRT) may be required in patients with severe AKI 
who develop medically refractory fluid and/or metabolic 
Box 4 | prevention of po- AKI: intraoperative strategies
Consensus Statement 4a
we recommend not using restrictive or zero- balance perioperative fluid regimens in 
major elective surgery (except in specific circumstances). such regimens are associated 
with increased risk of postoperative acute kidney injury (PO- aKi) (grade B evidence; 
strong recommendation).
Consensus Statement 4b
we recommend the use of goal- directed haemodynamic therapy in high- risk patients 
to optimize volume status, blood pressure and cardiac output and reduce the risk of 
PO- aKi (grade B evidence; strong recommendation).
Consensus Statement 4c
we recommend maintaining an intraoperative mean arterial blood pressure (MaP) 
>65 mmHg to reduce the risk of PO- aKi. the risk of aKi is a function of both the 
magnitude of hypotension and its duration. For selected patients, including those  
with pre- existing systemic hypertension, a higher MaP target should be considered 
(grade C evidence; weak recommendation).
Consensus Statement 4d
we recommend the perioperative use of balanced crystalloids rather than 0.9% saline 
to reduce the risk of PO- aKi (grade C evidence; strong recommendation).
Consensus Statement 4e
in the setting of elective surgery outside of the iCu, insufficient evidence exists to make 
a recommendation regarding the choice of crystalloids or colloids for volume expansion 
to modify the risk of PO-aKi (ungraded).
Box 5 | prevention of po- AKI: postoperative strategies
Consensus Statement 5a
we recommend maintenance of adequate organ perfusion, including attention to 
euvolaemia and treatment of hypotension in the early postoperative period, to reduce 
the risk of postoperative acute kidney injury (PO- aKi). Monitoring and targeting 
haemodynamic parameters may require enhanced levels of monitoring and/or care 
depending on the clinical context and patient risk profile (grade D evidence; strong 
recommendation).
Consensus Statement 5b
we recommend treatment of postoperative hyperglycaemia (target glucose <180 mg/dl 
[<10 mmol/l]) to reduce the risk of PO- aKi (grade C evidence; strong recommendation).
Consensus Statement 5c
we recommend considering restarting angiotensin- converting enzyme (aCe) inhibitor 
or angiotensin receptor blocker (arB) therapy within the first 48 h postoperatively in 
patients who are haemodynamically stable without evidence of PO- aKi. this decision 
should be individualized and context- specific (grade C evidence; strong 
recommendation).
Consensus Statement 5d
we recommend that enhanced recovery after surgery (eras) pathways (for example, 
use of NsaiDs and avoiding markedly positive fluid balance) are individualized  
based on the baseline risk of PO- aKi. the impact of eras pathways on the incidence  
of PO- aKi is unclear owing to the potential for both beneficial and harmful effects 
(grade C evidence; strong recommendation).
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complications. In the absence of conventional indica-
tions, the best timing for initiating KRT in PO- AKI is 
uncertain. Potential rationales for initiating KRT during 
PO- AKI are avoidance of fluid accumulation, mainte-
nance of acid- base and electrolyte control, provision 
of space to accommodate nutritional and medication 
needs, and abrogation of the interaction between the 
kidney and other organs. Theoretically, early initia-
tion of KRT could facilitate better fluid, electrolyte and 
acid–base homeostasis. However, KRT is associated with 
increased risk of complications, healthcare costs and 
clinical workload.
The 2012 KDIGO guidelines recommend starting 
KRT “when life threatening changes in fluid, electro-
lyte, and acid- base balance exist” and considering the 
“broader clinical context, the presence of conditions that 
can be modified with [KRT], and trends of laboratory 
tests — rather than single BUN and creatinine thresh-
olds alone — when making the decision to start [KRT]”. 
Contradictory trial results103,104 have stimulated debate 
regarding the best timing for KRT in patients with 
established AKI and differences in study design, patient 
populations, definitions of early and late RRT initiation, 
and inclusion criteria make head- to- head comparisons 
difficult.
Following our consensus conference, the results of 
the STARRT- AKI study provided high- quality evidence 
that early commencement of KRT based on AKI crite-
ria in the absence of conventional indications does not 
improve survival, may needlessly expose some patients 
to KRT and results in a higher risk of KRT dependence 
at 90 days compared with a conservative strategy for 
starting KRT105. Importantly, STARRT- AKI included 
a large cohort of patients with PO- AKI (n = 965) and 
showed no evidence of a benefit of early commence-
ment of KRT in this subgroup (odds ratio for mortal-
ity with earlier KRT: 1.20; 95% CI, 0.91–1.59). Thus, 
decisions regarding timing of KRT initiation remain a 
complex issue that should be individualized based on 
the clinical state of the patient, in particular imminently 
anticipated or observed life- threatening complications 
of AKI.
AKI subtypes. AKI is a heterogeneous condition consist-
ing of distinct endotypes and phenotypes based on its 
aetiology, prognosis and molecular pathways. Different 
subtypes might require and benefit from different ther-
apeutic strategies. However, current AKI definitions 
based on serum creatinine and urine output provide 
no information on AKI subtypes. Studies using various 
damage and functional AKI biomarkers suggest that 
these new tools might overcome the limitations of cur-
rent AKI definitions to improve AKI phenotyping106. 
Until these strategies are better embedded in clinical 
practice, the potential benefits of individualized therapy 
for AKI subtypes cannot be clearly established.
Table 1 | Adaptation of the KDIgo guidelines for treatment of AKI to the postoperative setting




In the absence of haemorrhagic shock, we suggest using a balanced and 
buffered isotonic crystalloid (e.g. Ringer’s lactate) rather than colloids 
(albumin or starches) as initial management for expansion of intravascular 
volume in patients with PO- AKI
Strong B
We recommend the use of vasopressors in conjunction with fluids  
in patients with vasomotor shock with PO- AKI
Strong D
We suggest using protocol- based management of haemodynamic and 
oxygenation parameters to treat patients with PO- AKI and to prevent 
worsening of AKI in high- risk patients in the perioperative setting
Strong D
We suggest insulin therapy targeting plasma glucose <180 mg/dl (10 mmol) 
in patients with PO- AKI
Weak Not graded
We suggest not using diuretics to treat AKI, except in the management  
of volume overload
Strong A
We recommend not using low- dose dopamine fenoldopam, atrial 
natriuretic peptide or recombinant human IGF1 to treat AKI
Strong A
We recommend not using nephrotoxic drugs in patients with PO- AKI unless 
no suitable, less nephrotoxic alternatives are available or the benefits 
outweigh the risks
Strong A
ADQI, Acute Disease Quality Initiative; AKI, acute kidney injury; IGF1, insulin- like growth factor I. KDIGO, Kidney Disease 
Improving Global Outcomes; PO- AKI, postoperative AKI; POQI, PeriOperative Quality Initiative. aAdapted from the treatment 
recommendations in the 2012 KDIGO clinical practice guideline for AKI54.
Box 6 | Treatment of po- AKI
Consensus Statement 6a
we recommend that the underlying causes of 
postoperative acute kidney injury (PO- aKi) should be 
determined and treated whenever possible (ungraded; 
strong recommendation).
Consensus Statement 6b
in patients with PO- aKi, we recommend that criteria for 
implementation of kidney replacement therapy (Krt) 
should be based on directly anticipated or observed 
life- threatening aKi- related complications (grade D 
evidence; strong recommendation).
Consensus Statement 6c
we suggest that aKi phenotype is taken into account 
when deciding what type of treatment to implement 
(ungraded; weak recommendation).
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Research recommendations. We recommend further 
trials to assess the optimal choice and volume of fluids 
for intravascular expansion and vasopressor therapy 
in patients with PO- AKI as well as the use of protocol- 
based management of haemodynamic and oxygen-
ation parameters to prevent worsening of PO- AKI. 
Investigation of individual components of the KDIGO 
guideline to identify those that are the most effec-
tive in treating PO- AKI is important given that these 
were largely assembled based on expert opinion. 
Better understanding of AKI phenotypes is required 
to enable further trials to assess the response to imple-
mentation of the KDIGO bundle and other treat-
ment options according to different AKI endotypes 
and phenotypes.
Outcomes of postoperative AKI and AKD
Regardless of the contributing mechanisms, PO- AKI 
has repeatedly been shown to be associated with a 
high risk of complications, including short- term and 
long- term mortality, high hospital costs and resource 
utilization6,29,31,39,40,107–115 (Fig. 4). Data from patients 
admitted to an ICU for at least 24 h following major 
surgery show that those who experienced PO- AKI had 
persistently worse survival over 10 years, even if kidney 
function recovered completely6. By contrast, a retrospec-
tive analysis of patients undergoing repair of ruptured 
abdominal aneurysm, a very high risk of acute expo-
sure, suggested long- term survival was not significantly 
different between those with and without AKI, perhaps 
as a result of the overwhelming influence of immediate 
surgical outcome in this setting31.
Patients with PO- AKI or AKD are at an increased 
risk of recurrent episodes of AKI and progressive dete-
rioration of kidney function, including CKD and dialysis 
dependency39. In patients undergoing major surgery, the 
incidence of kidney failure at 1 year was 0.94% among 
those who experienced AKI versus 0.05% in those who 
did not experience AKI39. Furthermore in a competing 
risk model accounting for death, adjusted progression 
to kidney failure during 10 years of follow- up was 0.4%, 
2.3%, 7.3% and 15.7% for patients with no kidney dis-
ease, AKI with no CKD, CKD with no AKI and AKI with 
CKD, respectively (P < 0.001)39.
Other postoperative complications, including infec-
tion, prolonged mechanical ventilation, tracheostomy 
and cardiovascular events are also more common in 
patients who develop AKI after surgery than in those 
who do not108. Among 1,200 patients who under-
went non- cardiac and non- vascular surgery, of whom 
6.7% met the RIFLE criteria for AKI (2), the risk of 
non- cardiovascular complications (such as pneumo-
nia and stroke) was similar in those with and without 
AKI over the first 2 weeks after surgery, but thereafter, 
patients with AKI experienced a significantly higher rate 
of cardiovascular events, including acute coronary syn-
drome, acute heart failure and arrhythmias107. Similarly, 
AKI after abdominal surgery has been associated with 
an increased risk of in- hospital complications, including 
perioperative acute myocardial infarction, pneumonia 
and sepsis (P < 0.001)29.
Unsurprisingly, the development of PO- AKI is asso-
ciated with substantial increases in hospital costs and 
resource utilization, as well as longer stays in the ICU 
and in hospital29,116,117. Furthermore, the risks of 30- day 
re- admission and discharge to a nursing facility or 
rehabilitation centre are increased31. PO- AKI has also 
been associated with important, but difficult to quan-
tify adverse outcomes, including reduced quality of life 
and perceived well- being118 as well as with increased 
risk of malignancy, possibly due to interactions with the 
immune system119.
Postoperative monitoring and management. Given the 
increased risk of short- and long- term adverse outcomes 
following PO- AKI, appropriate monitoring and follow 
up of this cohort is a potential approach to improving 
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Fig. 4 | outcomes of po-AKI and po-AKD. Postoperative acute kidney injury (PO- AKI) 
is associated with an increased risk of short- term adverse outcomes, including need for 
dialysis, cardiovascular events, lung injury, delirium and infection. These adverse effects 
can in turn lead to increased long- term morbidity and mortality. Adapted from Acute 
Disease Quality Initiative 24, www.ADQI.org, CC BY 2.0 (https://creativecommons.org/
licenses/by/2.0/).
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all- cause AKI have been proposed, the optimal timing 
of follow- up after a postoperative episode of AKI or 
AKD is unknown58,120 and limited evidence is available 
to support any specific monitoring paradigm. However, 
adverse outcomes are increased in patients with pro-
longed, more severe AKI, and in those whose kidney 
function does not recover to baseline levels, suggest-
ing that use of these factors to inform the initial fre-
quency and nature of follow- up would be a reasonable 
approach121,122.
Monitoring pathways should be developed in 
conjunction with nephrologists, but may be directly 
provided by perioperative physicians, primary care 
physicians or other specialists (Fig. 5). As a minimum, 
we recommend that all postoperative patients with AKI 
or AKD have a KHA within 30 days of hospital dis-
charge. To facilitate this assessment, accurate informa-
tion transfer from the hospital team to the primary care 
team and the patient or care giver is essential. At the very 
least, a post PO- AKI KHA should consist of checking 
glomerular filtration (e.g. serum creatinine levels) as 
well as other persistent signs of kidney injury (e.g. albu-
minuria). Screening for albuminuria 3 months after the 
development of AKI has been shown to identify those 
patients who are at a greater risk of CKD progression123. 
When available, further work- up and monitoring of kid-
ney function with other diagnostics may be appropriate. 
Changes in management based on this monitoring 
should be communicated with the patient as well as with 
other treating physicians.
In survivors of PO- AKI or AKD, the key priorities 
of long- term management are to facilitate kidney recov-
ery, prevent progressive CKD and mitigate long- term 
comorbidities, including cardiovascular risk. However, 
whether any effective strategies beyond supportive 
CKD care exist is unknown. ADQI recommends that 
a post- AKI or AKD care bundle should include assess-
ment of kidney function, advocacy and education, 
review and adjustment of medications, blood pres-
sure management and a sick day protocol58. A multi- 
disciplinary follow- up approach (involving nephrology, 
AKI or AKD severity
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Fig. 5 | potential monitoring approach for patients who experience po-AKI or po-AKD. Limited data are available  
to inform the timing and nature of monitoring for patients who experience postoperative acute kidney injury (PO- AKI) or 
postoperative acute kidney disease (PO- AKD). We suggest that these patients should have their kidney function checked 
within 1 month of hospital discharge to confirm the extent of recovery or progression of kidney disease. Those with 
persistent kidney dysfunction at 90 days should be formally assessed for the development or progression of chronic kidney 
disease (CKD). The degree of nephrology involvement in follow- up monitoring should increase with the duration and 
severity of AKI or AKD commensurate with the risk of developing CKD. Patients with less severe AKI or AKD can be monitored 
in primary care or by the base specialist and referred for nephrology care if needed according to CKD guidelines. Future 
research is needed to clarify the optimal timings and methods to provide post- AKI or AKD care. Adapted from Acute Disease 
Quality Initiative 24, www.ADQI.org, CC BY 2.0 (https://creativecommons.org/licenses/by/2.0/).
Box 7 | outcomes of po- AKI and po- AKD
Consensus statement 7a
the incidence of kidney and non- kidney adverse events is increased following 
postoperative acute kidney injury (PO- aKi) or postoperative acute kidney disease 
(PO- aKD). in particular, patients with surgery- associated aKi or aKD are at an 
increased risk of new or worsening chronic kidney disease (CKD), which is associated 
with increased long- term mortality (grade B evidence).
Consensus Statement 7b
the prevention of new or worsening CKD following an episode PO- aKi or PO- aKD is  
a public health priority. we recommend that all patients undergo at least one kidney 
health assessment once the acute phase of aKi or aKD is complete. this approach will 
require optimal communication and aKi education between health- care professionals 
and the patient or caregiver (grade B evidence; strong recommendation).
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primary care, pharmacy, a dietician, a social worker and 
non- nephrology subspecialists) combined with patient 
education is recommended but has not been formally 
studied. Undoubtedly, drug selection, dosing and moni-
toring are important and should be guided by personal-
ized clinical decision making and regular assessment of 
kidney function. Both the use of nephrotoxic drugs and 
the inappropriate exclusion of potentially beneficial medi-
cations (for example, ACE inhibitors or antidiabetic med-
ications) need to be avoided124,125. In patients with AKD, in 
particular, a substantial risk exists of potential therapeutic 
failure caused by underdosing or avoidance of effective 
cardiovascular drugs. Close collaboration between 
the relevant clinical teams is paramount and future 
research efforts should clarify the ideal timing and 
method for providing post- AKI and AKD care (Box 7).
Research recommendations. A need exists for epidemi-
ological research to describe the frequency, nature and 
severity of PO- AKI and PO- AKD progression to CKD. 
The effectiveness and cost- effectiveness of supplementing 
a simple KHA with enhanced kidney health care in the 
prevention of CKD progression after surgery- associated 
AKI or AKD should be evaluated in appropriately 
selected patients. Finally, research is needed to explore a 
possible common aetiology between surgery- associated 
AKI or AKD and other chronic organ injuries as the 
longer- term effects of AKI do not only involve the kidney.
Conclusions
PO- AKI is a sentinel postoperative event that is strongly 
associated with both short- term surgical complications 
and long- term adverse outcomes. In this Consensus 
Statement, we provide an overview of PO- AKI and 
management. However, PO- AKI is a heterogeneous 
syndrome with a variable clinical course. In many areas 
the strength of evidence is poor and accordingly our 
recommendations are weak. We provide research recom-
mendations for these areas to enable greater clarity to 
be achieved in the future. Overall, we believe that an 
integrated approach to PO- AKI management requires 
serial evaluations of AKI risk, diagnosis, progress and 
outcomes throughout the perioperative period, which 
can be constructed as a series of focused KHAs.
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